SE9101381D0 - PEPTIDE HORMONE SOLUTION - Google Patents

PEPTIDE HORMONE SOLUTION

Info

Publication number
SE9101381D0
SE9101381D0 SE9101381A SE9101381A SE9101381D0 SE 9101381 D0 SE9101381 D0 SE 9101381D0 SE 9101381 A SE9101381 A SE 9101381A SE 9101381 A SE9101381 A SE 9101381A SE 9101381 D0 SE9101381 D0 SE 9101381D0
Authority
SE
Sweden
Prior art keywords
hormone
peptide hormone
hormone solution
solution
peptide
Prior art date
Application number
SE9101381A
Other languages
Swedish (sv)
Inventor
Tomas Moks
Original Assignee
Tomas Moks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tomas Moks filed Critical Tomas Moks
Priority to SE9101381A priority Critical patent/SE9101381D0/en
Publication of SE9101381D0 publication Critical patent/SE9101381D0/en
Priority to PCT/SE1992/000283 priority patent/WO1992019260A1/en

Links

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Peptide hormone solution such as for injection or infusion, containing a hormone in a biologically effective amount dissolved in an aqueous vehicle, said solution containing serum albumin (SA) in an amount capable of stabilizing the hormone to prevent precipitation thereof; the use of such solutions in hormone pumps; and a method of treating diabetes.
SE9101381A 1991-05-07 1991-05-07 PEPTIDE HORMONE SOLUTION SE9101381D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE9101381A SE9101381D0 (en) 1991-05-07 1991-05-07 PEPTIDE HORMONE SOLUTION
PCT/SE1992/000283 WO1992019260A1 (en) 1991-05-07 1992-04-29 Peptide hormone solution

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9101381A SE9101381D0 (en) 1991-05-07 1991-05-07 PEPTIDE HORMONE SOLUTION

Publications (1)

Publication Number Publication Date
SE9101381D0 true SE9101381D0 (en) 1991-05-07

Family

ID=20382669

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9101381A SE9101381D0 (en) 1991-05-07 1991-05-07 PEPTIDE HORMONE SOLUTION

Country Status (2)

Country Link
SE (1) SE9101381D0 (en)
WO (1) WO1992019260A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5562510B2 (en) 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス Stable formulation of modified GLP-1
PL1633391T3 (en) 2003-06-03 2012-03-30 Novo Nordisk As Stabilized pharmaceutical peptide compositions
KR101308912B1 (en) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 Stabilized pharmaceutical peptide compositions
CN102784386A (en) 2003-11-20 2012-11-21 诺沃挪第克公司 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
EP1789434B1 (en) 2004-08-31 2013-11-20 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
CN105832658B (en) 2004-11-12 2020-07-31 诺和诺德公司 Stable formulations of insulinotropic peptides
US8865647B2 (en) 2009-11-02 2014-10-21 Novo Nordisk A/S Pharmaceutical solution of non covalently bound albumin and acylated insulin
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
WO2014096440A2 (en) 2012-12-21 2014-06-26 Novozymes Biopharma Dk A/S Composition
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
CA2927335C (en) 2014-10-27 2023-05-02 Aseko, Inc. Subcutaneous outpatient management
CA2993275C (en) 2015-08-20 2022-06-21 Aseko, Inc. Diabetes management therapy advisor
AR112480A1 (en) 2017-08-24 2019-10-30 Novo Nordisk As COMPOSITIONS OF GLP-1 AND ITS USES
US20230082544A1 (en) 2020-02-18 2023-03-16 Novo Nordisk A/S Pharmaceutical formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
CA1196863A (en) * 1983-06-08 1985-11-19 Mattheus F.A. Goosen Slow release injectable insulin composition
IT1222734B (en) * 1987-09-25 1990-09-12 Scalvo S P A PHARMACEUTICAL FORMULAS AND DOSAGE FORMS FOR RECTAL CALCITONIN SECTION
JPH0341033A (en) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd Stable preparation containing motilins

Also Published As

Publication number Publication date
WO1992019260A1 (en) 1992-11-12

Similar Documents

Publication Publication Date Title
SE9101381D0 (en) PEPTIDE HORMONE SOLUTION
ES2526707T3 (en) Purification and stabilization of peptides and proteins in pharmaceutical agents
ES2114183T3 (en) ANTIBODY FOR THE TREATMENT OF INSULIN DEPENDENT DIABETES.
SE8101065L (en) ANTITROMBINBEREDNING
JPS5536457A (en) Amino acid infusion
DE69220808T2 (en) DEVICE FOR ADMINISTERING MEDICINES
DK0607156T3 (en) Process for Preparing Preserved Drugs Containing Human Proteins for Infusion or Injection Purposes
KR920019371A (en) Stabilized Factor Ⅷ Formulations
DE3686654T2 (en) METHOD FOR ISOLATING RECOMBINANT POLYPEPTIDES IN BIOLOGICALLY ACTIVE FORM.
ATE120374T1 (en) LABELED POLYPEPTIDE DERIVATIVES.
DE69131847T2 (en) USE OF COPPER CONTAINING COPPER TO ACCELERATE Wounds Healing
KR910007542A (en) Sustained Release Compositions of Polypeptides
RU93053497A (en) NEW PEPTIDES-AGONISTS AND THEIR USE
ATE101650T1 (en) ACTIVATION OF GENOLOGICALLY MANUFACTURED ANTIBODIES EXPRESSED IN PROKARYONTS.
EP0526544A4 (en) Therapeutic uses of actin-binding compounds
IT1151741B (en) SOLUTION FOR DIALYSIS CONTAINING GLUCOSE, AMINO ACIDS AND INSULIN
DK0650729T3 (en) Rapamycin preparations for intravenous injection
DK0430200T3 (en) Polypeptide-containing drug for subcutaneous or intramuscular application
DE3650135D1 (en) Protein extraction.
UA26375A1 (en) METHOD OF PURIFICATION OF ISHULIH
ATE139451T1 (en) AQUEOUS PERITONEAL DIALYSIS SOLUTION
DK0607278T3 (en) Method of Intestinal Absorption Enhancement
RU93004696A (en) METHOD OF ADSORPTION WITH THE APPLICATION OF TANNIN
DE69322268T2 (en) STABLE COMPOSITION OF POLYPEPTIDES
ATE149834T1 (en) PYRIDYLGUANIDINE COMPOUNDS FOR THE TREATMENT OF ERECTIVE DISORDER